XXIV FERO Grant – Dr. Jon Zugazagoitia Fraile

Many patients with advanced lung cancer do not respond to available immunotherapies. With the support of the XXIV FERO Grant, Dr. Jon Zugazagoitia will investigate whether modulating the levels of the OX40L protein, a new molecular target, can help improve the efficacy of immunotherapy based on PD-1 axis blockade in lung cancer. To achieve this, they will use RNA technology to enhance OX40L and demonstrate its therapeutic potential. The project’s objective is to treat a greater number of lung cancer patients more effectively using new strategic immunotherapy approaches.